T Cell Non-Hodgkin Lymphoma

Systematic alanine scanning mutagenesis experimentally validated the predicted binding determinants, confirming the key residues within the macrocycle. Collectively, this work establishes macrocyclic phage display as a powerful and generalizable platform for discovering high-affinity ligands against challenging mutant GTPases and lays a foundation for the development of precision peptide-based therapeutics.

Multiplex single-molecule fluorescence ISH confirmed the presence of MCPyV in CD4+ T-cells. These findings support the hypothesis that MCPyV infection is specifically associated with rare CD4+ T-cell lymphomas, particularly in transplant recipients.

P1, N=36, Recruiting, Verismo Therapeutics | N=18 --> 36

Emerging biomarkers, including CD74, and acquired resistance mechanisms after anti-C-C chemokine receptor 4 therapy further extend the translational relevance of recent pathologic findings. Overall, CTCL evolution appears to be a systemic process shaped by interactions between tumor-intrinsic genetic alterations and the skin microenvironment.

This work demonstrates the feasibility of integrating single-cell and spatial analyses in GC lymphomas and provides a framework for investigating tumor heterogeneity and immune organization. These findings may inform future studies on biomarker development and the rational design of immunotherapies.

Biopsy of a spinal lesion demonstrated a T-cell lymphoma with diffuse EBV positivity and CD8 expression. The patient's disease was refractory to conventional chemotherapy with persistent/recurrent disease in other organ systems showing the aggressive nature of this disease and limited efficacy of standard regimens.

P1/2, N=25, Recruiting, Beijing Tongren Hospital

P1/2, N=96, Recruiting, Beijing Biotech

We describe four men (aged 44-65 years) with long-standing, severe CAD unresponsive to multiple systemic treatments, including immunosuppressants, dupilumab, and tofacitinib. Treatment was well tolerated, with only mild acneiform eruption and transient hypertriglyceridaemia in one case. These findings suggest that selective JAK1 inhibition may represent a therapeutic option in severe, treatment-refractory CAD.

Localized radiotherapy was then administered, which resulted in progressive improvement of the lesion from the first sessions, with tumor volume reduction, decreased exudate, and partial re-epithelialization of the ulcerated bed. This case highlights the role of localized radiotherapy as an effective palliative and disease-controlling modality for cutaneous CD30+ T-cell lymphoma, particularly in symptomatic or treatment-refractory lesions.

Lack of response, disease worsening, or emerging atypical features during therapy should prompt reassessment. These recommendations reflect expert consensus that is based on available evidence and highlight the need for prospective studies to better define risk profiles and guide patient selection.

Hypopigmented CD8+ MF in Sri Lanka represents an indolent clinicopathologic variant within the MF spectrum, recognition of which is essential to avoid misdiagnosis and overtreatment.